Moderna Inc (NASDAQ:MRNA) shares are trading higher by 9.7% at $149.11 after the company reported better-than-expected fourth-quarter results. Moderna reported quarterly earnings of $11.29 per share which beat the analyst consensus estimate of $9.90. The company reported quarterly sales of $7.20 billion which beat analyst consensus estimate of $6.79 billion by 6%. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the U.S. in December 2020. Modern . . .
[su_button url=’https://www.benzinga.com/trading-ideas/movers/22/02/25808962/whats-going-on-with-moderna-shares-today’ target=’_blank’ style=’ghost’ background=’#010066′ color=’#010066′ size=’2′ wide=’no’ center=’no’ radius=’auto’]Read more at www.benzinga.com[/su_button]
By
By
By
By
By
